Why You Should Have Attended the Cell & Gene Therapy Pricing & Reimbursement Summit
The 3rd Cell & Gene Therapy Pricing & Reimbursement Summit put attendees inside the conversations shaping how therapies actually secure access today.
Through case studies from recently approved companies, payer‑led discussions, and focused policy insights, attendees learned how to align evidence, pricing, and access strategy early to avoid delays post‑approval.
Across the program, you would have uncovered how to:
- Engage payers and treatment centres more effectively before and after launch
- Secure coverage by meeting evolving evidence expectations
- Navigate emerging payment models and policy shifts
- Remove access barriers to drive stronger, sustainable uptake
Built around real‑world lessons and practical frameworks, this meeting gave attendees the clarity needed to approach pricing and reimbursement with confidence in an increasingly demanding landscape.
What You Missed
Building a High Confidence Strategy from Launch to Year One
Attendees earned from Neurotech Pharmaceuticals’ first year commercial experience to understand how they built payer confidence prelaunch, aligned pricing with value expectations, and supported diverse practice settings through financial pathways that reduced provider risk and accelerated early Medicare claims.
Feeding Your Curiosity About the Cell & Gene Therapy Access Model in Practice
You would have learned directly from Genetix Biotherapeutics’ experience with the Cell and Gene Therapy Access Model to understand how early payer engagement, outcomes aligned contracting, and evidence generation accelerated patient adoption, and what manufacturers must provide to strengthen coverage pathways.
Understanding How Commercial & Employer Plans Evaluate Cell & Gene Therapies
Attendees went behind the scenes with Blue Cross Blue Shield and the Partnership for Employer-Sponsored Coverage to understand how carveouts, reinsurance structures, and affordability thresholds influence whether patients gain access, and at what speed.
Gaining Insight into Treatment Center Readiness & Real-World Delivery
Attendees understood the operational and financial realities treatment centres face with OneOncology, and heard more about Kite Pharma and Bristol Myers Squibb’s experiences with expanding their network treatment centres into the community oncology setting.
Explore the 2026 Event Guide
- 20+ speakers from leading cell and gene manufacturers, healthcare providers, commercial and government payers, and policy experts
- Network with 80+ like-minded professionals focused on addressing the latest policy and commercialization challenges for cell and gene therapies
- Hear case studies from involvement with the Cell and Gene Therapy Access Model, and the latest on launching a product in 2026
- The only meeting exclusively dedicated to market access, pricing, and reimbursement challenges for cell and gene therapies
Attending Companies Included
Explore the 2026 Agenda
Dive into the only agenda that unpacks real world cell and gene therapy pricing, reimbursement, evidence generation, payer strategy, and policy shifts shaping market viability today.
Partner With Us
Position your solutions at the center of cell and gene therapy market access, payer engagement, and commercialization strategy conversations attended by the field’s leading decisionmakers.
Join Biopharma Experts
Network with the manufacturers, payers, policy leaders, and access strategists defining the future of cell and gene therapy coverage, affordability, and sustainable patient access.